Preparation and Characterization of Meloxicam–Myrj-52 Granules Obtained by Melt Granulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Preparation and Characterization of Meloxicam–Myrj-52 Granules Obtained by Melt Granulation
Various manufacturing techniques can improve a drug's solubility, thus increasing its bioavailability. The authors examined whether melt granulation can enhance drug solubility using meloxicam as the drug substance and myrj-52 as the binder.


Pharmaceutical Technology


Samples equivalent to 15 mg of meloxicam were added to 900 mL of dissolution medium in a 1000-mL cylindrical beaker. The paddle speed was 100 rpm. At intervals of 5, 10, and 15 min, 10-mL samples were withdrawn during a period of 90 min. The same volume of preheated dissolution medium was infused into the medium after each sample was taken, to maintain a constant volume of the dissolution medium throughout the test. The samples were filtered using filter paper (41, Whatmann International, Maidstone, UK), and the meloxicam content was determined spectrophotometrically at λmax 363.5 nm using a Shimadzu UV-1700 spectrophotometer (Shimadzu). Data were analyzed with PCP-Disso software (Poona College of Pharmacy, Pune, India).

Permeation study. Female hairless mice (8–10 weeks old) were killed by cervical dislocation, and their full-thickness skins removed. The adhering fat and visceral tissue were removed. To remove extraneous debris and leachable enzymes, the dermal side of the skin was put in contact with a saline solution for 2 h. The dermal side was then treated with 1-mL phosphate buffer for 6 h to equilibrate the membrane before starting the diffusion experiment. The skin was stretched over the end of an open-ended glass tube. The tube was immersed in a 400-mL beaker containing 100-mL phosphate buffer (pH 7.4) and kept in a vertical position so that the membrane was below the surface of the buffer solution. The surface area available in diffusion was 2.5 cm2. The tube (donor) and beaker (receptor) were maintained at 37 °C and shaken in a thermostatically controlled shaker. A 3-mL aliquot of saturated buffer solutions (pH 7.4) of meloxicam as a pure drug and melt granules prepared with myrj-52 were inserted one by one into the tube. For 6 h, 5-mL samples were removed from the receptor at intervals and analyzed spectrophotometrically at 363.5 nm. The experiment was repeated three times, and the average of the readings was calculated.

Stability studies. For stability studies, about 200 mg each of pure drug, melt granulation, solid dispersion, and physical mixture were weighed into glass vials. The samples were monitored for three months at 30 °C and 60% relative humidity (RH). Samples were removed periodically and characterized by dissolution-rate measurement and the presence of crystallinity.

Preparation and characterization of tablets. Melt granules equivalent to 15 mg of meloxicam with 5% Ac-Di-Sol (FMC BioPolymer, Philadelphia, PA) were geometrically mixed and lubricated with 1% w/w magnesium stearate, which was manufactured according to Indian Pharmacopoeia standards. Formulations were passed through a #30 mesh sieve and directly compressed with a 12-station tablet machine (Minipress II MT, Karnawati Rimek, Ahmedabad, India) with an 8-mm punch diameter and circular punches with flat faces. The machine setting was adjusted to produce 160-mg tablets with a hardness of 3.5 6 0.25 kg/cm2 .


Table I: Studies of various tablet parameters.
The tablets' friability (n = 10) was determined with a friabilator (Roche, Veego Scientific, Mumbai, India). A hardness tester (Monsanto, LabHosp, Mumbai, India) determined the hardness of tablet samples (n = 10). The disintegration of tablets (n = 6) was determined using a disintegration-test apparatus (Veego Scientific) in distilled water at 37 ± 0.5 °C (see Table I).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here